Eli Lilly Receives FDA Approval for Zepbound in Obstructive Sleep Apnea

Eli Lilly and Company today announced that the FDA has approved Zepbound (tirzepatide) injection for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This is the first medication approved for OSA in the United States. In the Phase 3 SURMOUNT-OSA trials, Zepbound demonstrated significant reductions in the apnea-hypopnea index (AHI), with patients experiencing up to 62.8% reduction in AHI events per hour. Additionally, Zepbound significantly reduced body weight and improved cardiometabolic risk factors. This approval expands the therapeutic applications of tirzepatide beyond weight management and type 2 diabetes.